The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ABUS | +9.93% | +53.29% | +8.92% | -37% |
| S&P | +14.5% | +93.32% | +14.09% | +459% |
Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the Hepatitis B virus, SARS-CoV-2, and other coronaviruses. The company was founded on October 6, 2005 and is headquartered in Warminster, PA.
After a strong start to 2023, the virology-focused biopharma company has hit a regulatory speed bump.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $10.74M | 522.2% |
| Gross Profit | $10.73M | 683.1% |
| Gross Margin | 99.90% | 20.5% |
| Market Cap | $591.82M | 1.5% |
| Market Cap / Employee | $13.45M | 0.0% |
| Employees | 44 | -39.7% |
| Net Income | $2.52M | 112.7% |
| EBITDA | $1.92M | 109.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $37.41M | -40.4% |
| Accounts Receivable | $1.03M | -42.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $4.49M | -36.0% |
| Short Term Debt | $0.51M | 13.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -41.21% | 4.6% |
| Return On Invested Capital | -54.03% | 18.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$16.28M | -14.1% |
| Operating Free Cash Flow | -$16.28M | -14.1% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 6.82 | 5.80 | 6.81 | 7.47 | 53.90% |
| Price to Sales | 107.93 | 100.66 | 103.95 | 38.56 | -33.22% |
| Price to Tangible Book Value | 6.82 | 5.80 | 6.81 | 7.47 | 53.90% |
| Enterprise Value to EBITDA | -35.40 | -43.45 | -43.98 | 260.62 | -1326.63% |
| Return on Equity | -67.8% | -68.8% | -79.0% | -52.8% | -11.90% |
| Total Debt | $6.76M | $6.12M | $5.60M | $5.00M | -32.95% |
ABUS earnings call for the period ending June 30, 2022.
ABUS earnings call for the period ending March 31, 2022.
ABUS earnings call for the period ending December 31, 2021.
ABUS earnings call for the period ending September 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
